Significant progress was made in 2024, including refining the Phase 3 program to accelerate rilparencel's path to market in the U.S., the release of positive Phase 2 data, restarting manufacturing, an ...

With the right strategy, reaching LPI ahead of schedule isn’t a myth. Learn how some biotech and pharma teams are achieving ...

Pliant Therapeutics (PLRX) announced data from the first three of five potential cohorts of its ongoing Phase 1 dose escalation clinical trial ...

BioCity Biopharmaceuticals and MSD have signed a clinical trial partnership agreement to assess BC3195 in conjunction with ...

In this week’s InnovationRx newsletter, the worsening measles outbreak, a noninvasive brain-computer implant, replacing heart ...

Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a ...

FY 2024 revenue of $228.4 million, in-line with company guidance Commercial Cell & Gene Therapy revenue rose to $26 million in FY 2024, up 20% year-over-year Supporting ...

a crucial aspect of conducting successful early phase trials is the careful preparation of both investigational and non-investigational products to be used in a clinical trial setting. With ...

In spite of recent advances in the management of multiple myeloma, cure has been elusive, with efforts to improve long-term outcomes thwarted by repeated cycles of relapse and remission. This is ...

It is the "gold standard" lab test for clinical diagnosis and care and is used extensively in biomedical research ... sorting and analysis. Slug flow is a two-phase flow pattern observed when ...

The proportion increases when considering off-label use but drops when considering drugs with substantial clinical benefit. HealthDay News — One in 6 patients in phase 2 clinical cancer trials ...